Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2005-01-11
2005-01-11
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C514S002600, C424S234100, C424S247100
Reexamination Certificate
active
06841156
ABSTRACT:
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting ofBotulinumtoxin types A, B, C, D, E, F and G.
REFERENCES:
patent: 2373454 (1945-04-01), Bumy et al.
patent: 2719102 (1955-09-01), Baldwin
patent: 3132995 (1964-05-01), Berger et al.
patent: 4832936 (1989-05-01), Holter et al.
patent: 4935969 (1990-06-01), Dystra et al.
patent: 5053005 (1991-10-01), Borodic
patent: 5055302 (1991-10-01), Laties et al.
patent: 5056291 (1991-10-01), Leung
patent: 5183462 (1993-02-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 5401243 (1995-03-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 6290961 (2001-09-01), Aoki et al.
patent: 20020102275 (2002-08-01), Graham
patent: WO 940081 (1994-01-01), None
patent: 9400481 (1994-01-01), None
patent: WO 9428922 (1994-12-01), None
patent: 9528171 (1995-10-01), None
Borodic et al.BotulinumB toxin as an alternative to botunlinum A toxin: a histologic study. Ophthal Plast Reconstr Surg 1993; 9(3): 182-90 (IDS, Paper No. 5).*
Schantz et al. Properties and use ofbotulinumtoxin and other microbial neurotoxins in medicine. Microbiological Reviews, Mar. 1992; 56(1): 80-99 (IDS, Paper No. 5).*
Elston et al. Paralytic strabismus: the role of botulinum toxin. Br J Ophthalmol 1985 Dec.; 69(12): 891-6 (abstract).*
Adenis et al. Treatment of facial spasm withbotulinumA toxin. J Fr Optalmol 1990; 13(5): 259-64 (abstract).*
Correspondence dated Dec. 10, 1991 between William C. Shepherd and Ira Sanders.
Correspondence dated Apr. 13, 1992 between Ira Sanders and Angelika S. Aswad Regarding “Animal Study”.
Partial Correspondence dated Apr. 24, 1992 between Angelika S. Aswad and Dr. Sanders Regarding “BotulinumToxin to Decrease Salivary Flow”.
Ambache, J. Physiol. (1951) 113, 1-17.
Ambache, J. Physiol. (1949) 108, 127-141.
Brin; Arch. De Neurobiol. 54. Supl. 3 (7-23) 1991.
Jenzer et al; Schweiz. Med. Wschr. (1974); 104, 685-693 (w/English translation).
Poungvarin et al; J. Med. Assoc. Thai. (Apr. 1992) 75 (4) 199-203.
Greene, Paul E., et al.;Response to Botulinum Toxin F in Seronegative Botulinum Toxin A-Resistant Patients; Movement Disorders; vol. 11, No. 2; pp. 181-184 (Mar. 1996).
Moyer, E.D., et al.;Effects of Intramuscular Injection of Botulinum Toxin Type B in Nonhuman Primates; Botulinum and Tetanus Neurotoxins—Neurotransmission and Biomedical Aspects; Bibhuti R. Dasgupta, Editor; Plenum Press (1993).
Price, J., et al.;A Comparative-Study of Tear Secretion in Blepharospasm and Hemifacial Spasm Patients Treated with Botulinum Toxin; Journal of Clinical Neuro-Ophthalmology; vol. 13, No. 1; pp. 67-71 (Mar. 1993). Abstract only.
Scott, Alan B., et al.;Systemic Toxicity of Botulinum Toxin by Intramuscular Injection in the Monkey; Movement Disorders; vol. 3, No. 4; pp. 333-335 (1988).
Truong, Daniel D., et al.;BotB(Botulinum Toxin Type B):Evaluation of Safety and Tolerability in Botulinum Toxin Type A-Resistant Cervical Dystonia Patients(Preliminary Study);Movement Disorders; vol. 12, No. 5; pp. 772-775 (Sep. 1997).
Tsui, J.K., et al.;A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis; The Canadian Journal of Neurological Sciences; vol. 12, No. 4; pp. 314-316 (Nov. 1985).
Tsui, Joseph K.C., et al.;Local Treatment of Spasmodic Torticollis with Botulinum Toxin; Le Journal Canadien des Sciences Neurologiques; vol. 14, No. 3 (Supplement); pp. 533-535 (Aug. 1987).
Med Ad News staff;Athena Makes a Wise Move; Medical Advertising News; p. 4 (Nov. 1992).
U.S. Food and Drug Administration;List of Orphan Designations and Approvals; pp. 1 and 42-46 of 275 (computer search printout dated Jan. 18, 2000).
Borodic, G.E., et al.,Botulinum B Toxin as an alternative to Botulinum A Toxin: A Histologic Study, Ophthalmic Plastic and Reconstructive Surgery, vol. 9, No. 3, pp 182-190, 1993.
Schantz, E.J., et al.,Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews, Mar. 1992, pp. 80-99, vol. 56, No. 1.
Sellin, L.C., et al.,Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction, Acta Physiolo Scand 1983, 119:127-133.
Aoki K. Roger
Carlson Steven R.
Grayston Michael W.
Leon Judith M.
Allergan Inc.
Audet Maury
Donovan Stephen
Tate Christopher R.
LandOfFree
Method for treating muscle spasm with botulinum toxin type B does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating muscle spasm with botulinum toxin type B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating muscle spasm with botulinum toxin type B will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3434063